{"name":"Elite Laboratories, Inc","slug":"elite-laboratories-inc","ticker":"","exchange":"","domain":"elitelaboratories.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Oxycodone Naltrexone (a)","genericName":"Oxycodone Naltrexone (a)","slug":"oxycodone-naltrexone-a","indication":"Moderate to severe chronic pain","status":"phase_3"},{"name":"Oxycodone Naltrexone (b)","genericName":"Oxycodone Naltrexone (b)","slug":"oxycodone-naltrexone-b","indication":"Moderate to severe chronic pain","status":"phase_3"},{"name":"Oxycodone/Naltrexone Capsules","genericName":"Oxycodone/Naltrexone Capsules","slug":"oxycodone-naltrexone-capsules","indication":"Moderate to severe chronic pain where the need for an opioid analgesic is required, and for which alternative treatments are inadequate","status":"phase_3"}]}],"pipeline":[{"name":"Oxycodone Naltrexone (a)","genericName":"Oxycodone Naltrexone (a)","slug":"oxycodone-naltrexone-a","phase":"phase_3","mechanism":"Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.","indications":["Moderate to severe chronic pain"],"catalyst":""},{"name":"Oxycodone Naltrexone (b)","genericName":"Oxycodone Naltrexone (b)","slug":"oxycodone-naltrexone-b","phase":"phase_3","mechanism":"Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.","indications":["Moderate to severe chronic pain"],"catalyst":""},{"name":"Oxycodone/Naltrexone Capsules","genericName":"Oxycodone/Naltrexone Capsules","slug":"oxycodone-naltrexone-capsules","phase":"phase_3","mechanism":"Oxycodone/Naltrexone capsules combine an opioid analgesic with an opioid antagonist to provide pain relief while reducing the risk of misuse and dependence.","indications":["Moderate to severe chronic pain where the need for an opioid analgesic is required, and for which alternative treatments are inadequate"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOaXBzTEFGVVNxaW0tWEE0Z093VEFiS0NQQy1Ibk9ibXVWUVNUUUt0QUFNZmktNm1SVzM1VlNTR3VWSVRGcVNnX0VFRDd3cXduQ3E5SnUwU0RvQ2xrMnJ3ZEFsTGlzSGNiazF0a1N5QlU2Nkw0OVdiNmVidUEzblRkZk5OUkVVaS1QSDFVOUtXdVlYdkVLNWlRSk5SSU5oelh3LVhrcHBpMlBZWVdGQlRwNy1wd2tmaGdRTXc?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance","summary":"Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets - Yahoo Finance","headline":"Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTG0wd1ZFWmE0aGtGMk5ZNXVJem5yMEs1Vldla19EeWVSZG5vX3MwRDJ0bmdQY2JxV1hSVUpZQ0pHNjZhRTdaTW1ETTJEemZsZkx4OWlydU8wX0tRQUlLZ3QzX1loRmFMemJRMkx2UFkxWFNyMnZFcG5mLUd6dXhVWU9FTF9HUy1kcUZaUU1BMWV5YUdOdkxRS0dTOElDbzJEMDhpRFhTdnlRMnNWVVBHQU0tamxJUkE1?oc=5","date":"2026-04-02","type":"patent","source":"Stock Titan","summary":"Elite brings generic methadone tablets to market in $22M category - Stock Titan","headline":"Elite brings generic methadone tablets to market in $22M category","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPY20zODhxR3BxdUthaHFrUUQ0SlFla2hWbTRYY2VNVkcwalBzM3QwMVpGa2lHbWJzT2E2QV8zRW1uUHRienhRN1BoV0p5YlU2QUpleUNKVUhLYTlxdFdHekZta2hVdEZ4VXFUdlZQMUhxUXU3OGNrdm5zeUp2SU5wcTZYLVNUdWlnRjBha20zVmoxZi1JMlZxeDhHZjFEMFZkLXlZTVhHRTJidHY1Q05JVnR6VHJqOW1q?oc=5","date":"2026-04-02","type":"patent","source":"TipRanks","summary":"Elite launches generic methadone tablets, expanding pain portfolio - TipRanks","headline":"Elite launches generic methadone tablets, expanding pain portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOejRTRkNHZEZuVzR1ZWc5WGZoYWVvRlZ6cE9DZUpERWtsc2pFSEVwVXdDSk5RbURZdFduamZackRoaDlNVWQtZHR4Z0o2b0NaMUo1Q0lSY0NMQVM0RDdlNHRZTFdQSWVpeTA5dDU3eHFLTnRXZVJTN2ZGc1Q5aXVnQ19pS29ubXpnNHRFcVMwdmlEVkhqWFliX0VWbGN3d0RCcTRGQU9Hc3pkbndLTGFvMThB?oc=5","date":"2026-04-02","type":"patent","source":"Investing.com UK","summary":"Elite Pharmaceuticals launches generic methadone tablets By Investing.com - Investing.com UK","headline":"Elite Pharmaceuticals launches generic methadone tablets By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPTVhtcGFKZWtDZU40NDBOdjFvemFSNTBwUW5CeUZBY003amxYZjZZZlVzcW0yZTEyRTlMbFB5TWtQVG53enJleEFxYmtQX2RveUQ1a2NMZFlYVXVGTlA0ZXhvNFdEQklITGdHRGNIM3Rjc2hsa1dFeDRHOUE4Ykt0REJ1VGdQNkw1Q2Z3R0s3TVNuNUFidDRXV1ExSU9tUnNvRzJxLUNwZEZpeGFNdlhvdll3?oc=5","date":"2026-04-02","type":"patent","source":"Investing.com Canada","summary":"Elite Pharmaceuticals launches generic methadone tablets By Investing.com - Investing.com Canada","headline":"Elite Pharmaceuticals launches generic methadone tablets By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNNGEzTC1OMTEwUDljTk9YZ0U1ZHE0X3NwbGZzMDBxU2VYVXpOTHptcHBXcmhZX1g5dXcyV2lucXMwNXZDVUJFN1haY1YtMHNUS3pSbFN2OFZ3eGcycGJlZzZXTXV5WUgwQkhSWjlma21xRDVKZ3oyb3R2cThYLWxhUHdaVFVWVDJYNHhYYTFaTDdPSE0?oc=5","date":"2026-02-17","type":"earnings","source":"Yahoo Finance","summary":"Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information - Yahoo Finance","headline":"Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended Dece","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxON2tuQlBqV0lfVHpXZlpZM2c3RU0zVFZ1YmRZcE1mS1hwVlZEQVNoYzU4S1YyekgyX2FkdlowMVZCOG4yd3RHb0RLMUVRaTN0bVdabU84cDdCTHZpVFBoakZQVWFWblNWQThlNnotM2xMSlZMaUZpM05lSUx4M2h2VWdqdjJTdEktb1BUTVI2Umo4R3FiY0dJdndrZnd5b0ZreTJsZ2VVS1kyNFo1SjZsYkFLenNlS0x2b0pQYQ?oc=5","date":"2026-02-17","type":"earnings","source":"Stock Titan","summary":"Elite Pharma profit surges 721% as new generic drugs lift sales - Stock Titan","headline":"Elite Pharma profit surges 721% as new generic drugs lift sales","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbHRhZWFCTkc0SXdBNHU4bUUzdVBCNUNiQnFHdEtXMjBOV1N3aFQyWlJLbzFldU5jNFFHQXlTeURfalhKdTRmdmFLTWpZbE4tRTZFWU1LbWFDX2kyVVBtZUktZkVncWZLY0JNUElOb3ZhWjFzZUFBYU5odEd2ZmdPbEt1bUxtMklBUEYyX1MxQXVrZVc2ZlJnWmtiUzBSVFRSOEhqN2dieVVYUDNvVUJDRkd3?oc=5","date":"2026-02-17","type":"earnings","source":"TipRanks","summary":"Elite Pharmaceuticals Delivers Strong Fiscal Q3 2026 Results - TipRanks","headline":"Elite Pharmaceuticals Delivers Strong Fiscal Q3 2026 Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNOFdWUzZpOHYxMjZIMURkYzVFczJ6Z21TU2h0SWd6M1NHQlBEUFYweHF1UFpPdUZlN3huZFlUQzdTVDNicnZ4MFRoX0NlMkhoOUViRU5JUDhtSFlXYVc1dmQ1NHBPNXJjdWVXbW10TkE2Y1hTZ19OOUhpRG5UNFhTcFdJd21GLXJWZ1pXTEJ1WXV2RkpqZ2NzN1g4cktWLWc4V2EzQzFKRFhBTFgzU1JNTnB4Z1YxdXlMX25yNHl1ME1YMjRIdjNycnFIaXkxR2t1Q0czYkdOWi1WbDU0bHZub1NJbVhyYmlFX1BhaC1ndUxQbG5xMUYzbTZBV2hMRGt4ZUh2M0pRMWJ6Q3pNVE94d0FXNUtFUFI3TE1ZeGJ5dHJDVFJrRGJ6R1ZFZVpfeElSeW10VzlBU0drM3I4NkwyU1NIUEo?oc=5","date":"2026-02-11","type":"earnings","source":"TradingView","summary":"Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 - TradingView","headline":"Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNdXdkY055SzRZeFQ3dFNJYzVvMnUwZ05ISnFmRkZnd3I0S1o2alRTTE1tbWN5WUVxTC1faXhNWUp3aE9VQWp0WVJwOFV1VzRzSnJWYmxSVjMtWFBwSXQ5U0oxVFZYUzFnUVlMbWxmc3RaWGZSZTVIQzcyYnlYelRoa3NsbmI4Q0VGWFg1QXctVXk4SFE2RmZBMkxJOEtveUltckxNQ0JZUVVNQThPVFI0YlZuSEZNLVBmOE1GXw?oc=5","date":"2025-11-12","type":"regulatory","source":"Stock Titan","summary":"Elite Pharma (OTCBB: ELTP) secures FDA approval for generic Requip XL; $10M U.S. sales - Stock Titan","headline":"Elite Pharma (OTCBB: ELTP) secures FDA approval for generic Requip XL; $10M U.S. sales","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQdzVLSWJIUHFwaW8wbzl1ZjR0NVA1eGY5akw2aUhUejMtdTA3VHR6cUtwbWdFV01Zak1haVJlaXIySTVETXVlYXpETWp1bWJCdERhYVNlM1NJT1o2NkNpeFNBcU8yS21SZmd2TFlCR1Z1dkNsRHBibHRsMW9qb2VjNmQwVEpFU3hBb0dFa3RwbG5hc1Fudk53RUN4LXVfXzllUGJTTFIzZFhoNkkzNnJIS0thMFVkdw?oc=5","date":"2025-11-10","type":"earnings","source":"Stock Titan","summary":"Elite Pharma (OTCQB: ELTP) sets Nov 17 call on FY26 second-quarter results for investors - Stock Titan","headline":"Elite Pharma (OTCQB: ELTP) sets Nov 17 call on FY26 second-quarter results for investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPSEhRaHc4NkVzQ1kxaXFhWWlEMXBITEhuOTdMcGdFWWhOVlRVUHY5c1l6QTctbGFVWE9BWkV0MkVvbThUdEQzcTRNU1pDMVRsNmlzWkU1S3lIMVZ2QnY5SU1rSXRSUEFPMEhjaG5xd0VLbkpwTkN2YWM4WmZlbTNSeW1mTDRYN2o5NDNmN1k2N3NkOHc?oc=5","date":"2025-08-14","type":"earnings","source":"Yahoo Finance","summary":"Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information - Yahoo Finance","headline":"Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and ","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}